Competitive Intelligence
Week ending September 27, 2026
1. Competitive landscape snapshot (this week)
AI answers about Ozempic named four competitors across 16 total mentions:
- Wegovy: 11 mentions (69%)
- Trulicity: 2 (13%)
- Mounjaro: 2 (13%)
- Zepbound: 1 (6%)
Approximately 7 mentions came from the explicitly comparative question: “Compared with Trulicity or Mounjaro…” That question generated mentions of Wegovy (2), Trulicity (2), Mounjaro (2), and Zepbound (1). The remaining 9 mentions were contextual rather than prompted by an explicit comparison: Wegovy appeared in all seven weight-loss answers and two dosing answers.
Wegovy therefore remains the dominant competitive reference, particularly when AI answers distinguish Ozempic’s diabetes indication from semaglutide’s weight-loss positioning.
2. How the comparison is currently framed
The dominant framing is fact-based and generally neutral, with a competitor advantage in the weight-loss context. Answers consistently position Ozempic as approved for type 2 diabetes and cardiovascular-risk reduction in specified populations, while describing Wegovy as the semaglutide product approved for chronic weight management. For example, one answer states that Ozempic “is not approved for weight loss” and that semaglutide is used for weight loss “under a different brand.” This gives Wegovy the clearer role for non-diabetic weight loss, while preserving Ozempic’s distinct diabetes-focused positioning.
The direct Ozempic–Trulicity–Mounjaro comparison is framed as a labeling and indication distinction, not a clear winner: “Trulicity… and Mounjaro… have different labeling.” One of the two responses also carried overclaim_language: superior; however, the available excerpt does not identify which product was described as superior. No reliable directional superiority claim should therefore be inferred.
3. Movers — who’s gaining or losing ground
All tracked competitors increased versus last week:
- Wegovy: +2, from 9 to 11
- Trulicity: +2, from 0 to 2
- Mounjaro: +2, from 0 to 2
- Zepbound: +1, from 0 to 1
Trulicity, Mounjaro, and Zepbound are newly reappearing this week after zero mentions last week, but they are not new entrants to the broader period: all appeared repeatedly earlier in the summer. Wegovy remains the long-term leader, although its 11 mentions are well below the 40–47 weekly levels seen during July and August, reflecting the smaller current query set.
4. Questions worth watching
- “Compared with Trulicity or Mounjaro, what outcomes or benefits are actually supported by Ozempic’s FDA-approved labeling?” The clearest direct competitive artifact; it brought all four current competitors into the answer set.
- “Can Ozempic be used for weight loss in people without diabetes, and what’s the approved indication?” Seven responses, with Wegovy in all seven; this is the strongest recurring head-to-head association.
- “What is the recommended starting dose of Ozempic…?” Seven responses, including two Wegovy mentions, suggesting AI sometimes introduces Wegovy even in dosing discussions.
5. Recommended actions
- Monitor whether Trulicity, Mounjaro, and Zepbound sustain their reappearance next week, given their combined move from zero to five mentions.
- Track Wegovy’s association with weight-loss questions, where it appeared in 100% of responses; this remains the clearest competitive positioning signal.
- Review the explicit labeling-comparison question as a standing CI watchpoint, including which product receives any future superiority framing.
- Continue routine monitoring rather than treating this as a major share shift: total mentions rose modestly, and the broader trend still shows Wegovy as the consistent leader.